Skip to content

Internet Buzz On Sarepta Therapeutics’ Orphan Drug Eteplirsen For Duchenne Muscular Dystrophy (DMD)

October 13, 2012

    The Internet Buzz on Sarepta Therapeutics’ orphan drug Eteplirsen for Duchenne Muscular Dystrophy (DMD) :

1)  At the 2012 World Muscle Society Congress in Perth, Australia, on Saturday, October 13, 2012, 4:00 AM ET/4:00 pm AWDT, Sarepta Therapeutics presented an abstract titled, “Results at 48 Weeks of a Phase IIb extension study of the exon-skipping drug Eteplirsen in patients with DMD”.  The presentation was made by principal investigator, Jerry R. Mendell, MD of Nationwide Children’s Hospital

2)  Sarepta Therapeutics October 12, 2012 Press Release  

3) October 12, 2012 Article titled,”Sarepta to update on additional Eteplirsen Phase IIb data”   

4) October 13, 2012 Article titled,”Sarepta Discloses Dystrophin Expression Data at World Muscle Society Congress”   

5) October 4, 2012 Article titled,”Sarepta Fails to Report Meaningful Dystrophin Expression Data, Falls Behind Prosensa”.  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: